Forxiga 5 mg (Dapagliflozin Propanediol Hydrate)
Dapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.
MFDS item code 201310307 · Approved 2013.11.26
This product's status changed to Approval withdrawn on 2024.04.25. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of blood glucose control in type 2 diabetes; treatment of chronic kidney disease and chronic heart failure
This medication is used along with dietary and exercise therapy to improve blood sugar control in patients with type 2 diabetes. Additionally, it helps reduce the risk of death and hospitalization due to cardiovascular diseases in patients with chronic heart failure. It is also used to reduce risks associated with declining kidney function in patients with chronic kidney disease. Thus, it is effective in the treatment of type 2 diabetes, chronic heart failure, and chronic kidney disease, aiding in the overall improvement of patients' conditions.
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, including insulin. When this medicine is used in combination with insulin or insulin secretagogues such as sulfonylureas, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients with no prior experience of diabetes drug therapy, when administered in combination with metformin, the recommended initial dose of this medicine is 5mg once daily or 10mg once daily. Chronic heart failure and chronic kidney disease The recommended dose of this medicine is 10 mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this medicine to improve glycemic control is not recommended. - eGFR less than 25 mL/min/1.73m2: Initiation of this medicine is not recommended in patients with chronic heart failure and chronic kidney disease. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, 5 mg is recommended as the starting dose. If well tolerated, this dose may be increased to 10mg. Elderly patients (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be administered orally once daily at any time of day, with or without food. The tablet should be swallowed whole.
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.
This medication should not be used by individuals who are allergic to its active ingredient or any of its additives. It should not be administered to patients with type 1 diabetes or those with diabetic ketoacidosis. It contains anhydrous lactose, so individuals with genetic issues like galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption should not take it. Patients on dialysis should not use this medication. Patients with dehydration or kidney function issues should use this medication with caution. This medication may lower blood pressure and reduce intravascular volume, posing a risk of symptomatic hypotension or acute kidney injury. Particularly in the elderly, patients on diuretics, or those with reduced kidney function, fluid status and kidney function should be carefully evaluated before administration. The medication is not recommended for patients with severely reduced kidney function, as its blood sugar control effects may be diminished. Infections such as genital infections and urinary tract infections may occur during treatment; any symptoms should be treated promptly. Hypoglycemic symptoms may appear; therefore, dosage adjustments may be necessary when taken with medications like insulin or sulfonylureas. Symptoms of dehydration such as decreased fluid volume, dry mouth, and dizziness may occur, highlighting the importance of fluid intake and monitoring for symptoms. Serious metabolic disorders such as diabetic ketoacidosis may develop; if symptoms like vomiting, abdominal pain, or difficulty breathing occur, immediate consultation with healthcare personnel is advised. This medication is not recommended for pregnant or breastfeeding women, and should be discontinued upon confirmation of pregnancy. It is not used in children, as safety and effectiveness have not been established. There is no specific antidote for overdose, so symptomatic treatment is crucial. This medication does not significantly affect driving or the operation of machinery, but caution is necessary due to the risk of hypoglycemia. Lastly, this medication should be stored out of reach of children and kept in its original container to maintain quality.
Vulvovaginitis, balanitis and related genital infections, urinary tract infections, fungal infections, perineal necrosis, hypoglycemia, decreased fluid volume, thirst, diabetic ketoacidosis, dizziness, constipation, dry mouth, lumbago, dysuria, polyuria, nocturia, interstitial nephritis, vulvar pruritus, genital pruritus, increased hematocrit, decreased renal creatinine clearance at the beginning of treatment, dyslipidemia, increased serum creatinine at the beginning of treatment, elevated blood urea, weight loss, acute pyelonephritis, rash, asthenia, pain, keratitis, chronic obstructive pulmonary disease, hemoptysis, cerebral hemorrhage, peripheral arterial occlusion, angina pectoris, myocardial infarction, biliary stones, cholangitis, alcoholic cirrhosis, depression, suicide attempt, stomach adenocarcinoma, anaphylactic reaction, sensory abnormalities, cerebral infarction, nerve compression, sensory loss, headache, nasopharyngitis, upper respiratory infection, chest pain, fatigue, chest discomfort, peripheral edema, generalized edema, hunger, vaginal discharge, menstrual irregularities, pruritus, urticaria, cold sweat, arthralgia, musculoskeletal pain, limb pain, muscle weakness, myalgia, osteoarthritis, ligament strains, diabetic retinopathy, cough, dyspnea, orthostatic hypotension, palpitations, insomnia, fatty liver, gallbladder polyp, tinnitus
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to avoid contact with air or moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius to preserve the medication's effectiveness over time.
Yellow, double-sided, convex, round film-coated tablet
28 tablets (7 tablets/PTP × 4), 30 tablets (10 tablets/PTP × 3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.
Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.
Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Il Sung IS Co., Ltd.
Dapagliflozin Propanediol Hydrate
Prescription medication
Optus Pharmaceutical Co., Ltd.

Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Aprogen Biologics Co., Ltd.

Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Il Yang Pharmaceutical Co., Ltd.

Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Daewoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.